LON:HIK - Hikma Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: GBX 2,717.50
  • Forecasted Upside: 10.11 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
GBX 2,468
▲ +21 (0.86%)
1 month | 3 months | 12 months
Get New Hikma Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HIK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HIK

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
GBX 2,717.50
▲ +10.11% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Hikma Pharmaceuticals in the last 3 months. The average price target is GBX 2,717.50, with a high forecast of GBX 2,860 and a low forecast of GBX 2,600. The average price target represents a 10.11% upside from the last price of GBX 2,468.

Buy

The current consensus among 5 contributing investment analysts is to buy stock in Hikma Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings
12/22/2019
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 1 sell ratings
3/21/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings
6/19/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 1 sell ratings
9/17/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/16/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/16/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/15/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/14/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
6/8/2021Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellReiterated RatingBuyGBX 2,610
i
5/6/2021BarclaysReiterated RatingOverweightGBX 2,800
i
2/1/2021CitigroupReiterated RatingBuy
i
9/2/2020Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellReiterated RatingBuy
i
9/2/2020CitigroupReiterated RatingBuy
i
7/30/2020Peel HuntBoost Price TargetBuyGBX 2,380 ➝ GBX 2,860
i
7/7/2020Morgan StanleyUpgradeOverweightGBX 2,200 ➝ GBX 2,600
i
7/2/2020Peel HuntReiterated RatingBuy
i
6/23/2020Peel HuntReiterated RatingBuy
i
6/3/2020Peel HuntReiterated RatingBuy
i
5/22/2020Peel HuntReiterated RatingBuy
i
4/30/2020Peel HuntReiterated RatingBuy
i
4/28/2020BarclaysBoost Price TargetEqual WeightGBX 1,950 ➝ GBX 2,200
i
4/24/2020The Goldman Sachs GroupDowngradeNeutralGBX 2,200 ➝ GBX 2,400
i
4/24/2020Peel HuntReiterated RatingBuy
i
4/3/2020CitigroupBoost Price TargetBuyGBX 2,150 ➝ GBX 2,500
i
4/2/2020JPMorgan Chase & Co.UpgradeOverweightGBX 1,850 ➝ GBX 2,400
i
4/2/2020Peel HuntUpgradeBuyGBX 1,990 ➝ GBX 2,380
i
3/31/2020Peel HuntReiterated RatingHold
i
3/12/2020Jefferies Financial GroupBoost Price TargetBuyGBX 2,300 ➝ GBX 2,390
i
3/10/2020CitigroupUpgradeBuyGBX 1,980 ➝ GBX 2,150
i
3/5/2020Peel HuntReiterated RatingHold
i
3/2/2020BarclaysBoost Price TargetEqual weightGBX 1,900 ➝ GBX 1,950
i
2/28/2020JPMorgan Chase & Co.Reiterated RatingUnderweight
i
2/28/2020CitigroupReiterated RatingNeutral
i
2/24/2020Peel HuntReiterated RatingHold
i
2/20/2020BarclaysReiterated RatingEqual weight
i
2/18/2020Peel HuntReiterated RatingHold
i
2/17/2020CitigroupDowngradeNeutral
i
2/5/2020Peel HuntReiterated RatingHold
i
1/27/2020Peel HuntReiterated RatingHold
i
1/21/2020Jefferies Financial GroupLower Price TargetBuyGBX 2,310 ➝ GBX 2,240
i
1/20/2020BarclaysReiterated RatingEqual WeightGBX 1,900
i
1/10/2020Peel HuntReiterated RatingHold
i
1/6/2020JPMorgan Chase & Co.Boost Price TargetNeutralGBX 1,800 ➝ GBX 1,850
i
12/6/2019BarclaysReiterated RatingEqual weight
i
12/5/2019Peel HuntReiterated RatingHold
i
12/3/2019JPMorgan Chase & Co.Boost Price TargetNeutralGBX 1,700 ➝ GBX 1,800
i
11/27/2019Peel HuntReiterated RatingHold
i
11/27/2019HSBCReiterated RatingReduce
i
11/18/2019BarclaysReiterated RatingEqual weight
i
11/15/2019Jefferies Financial GroupReiterated RatingBuy
i
11/13/2019Morgan StanleyReiterated RatingEqual weight
i
11/7/2019CitigroupReiterated RatingBuy
i
11/4/2019Peel HuntReiterated RatingHold
i
9/2/2019Peel HuntReiterated RatingHold
i
8/20/2019BarclaysBoost Price TargetEqual weightGBX 1,800 ➝ GBX 1,900
i
8/9/2019Peel HuntReiterated RatingHoldGBX 1,870 ➝ GBX 2,050
i
7/29/2019Peel HuntReiterated RatingHold
i
7/3/2019Peel HuntReiterated RatingHold
i
6/18/2019JPMorgan Chase & Co.Reiterated RatingNeutralGBX 1,700
i
6/4/2019Peel HuntReiterated RatingHold
i
5/17/2019Peel HuntReiterated RatingHold
i
5/3/2019BarclaysReiterated RatingEqual WeightGBX 1,800
i
5/2/2019Peel HuntReiterated RatingHold
i
4/10/2019BarclaysReiterated RatingEqual weight
i
4/2/2019Peel HuntReiterated RatingHold
i
3/21/2019BarclaysLower Price TargetEqual weightGBX 1,950 ➝ GBX 1,800
i
3/19/2019CitigroupUpgradeBuy
i
3/19/2019Jefferies Financial GroupLower Price TargetBuyGBX 2,000 ➝ GBX 1,960
i
3/14/2019HSBCBoost Price TargetReduceGBX 1,225 ➝ GBX 1,350
i
3/14/2019JPMorgan Chase & Co.Lower Price TargetNeutralGBX 1,800 ➝ GBX 1,700
i
3/13/2019Numis SecuritiesReiterated RatingHoldGBX 1,730
i
3/12/2019Peel HuntLower Price TargetHoldGBX 2,000 ➝ GBX 1,870
i
1/31/2019Peel HuntReiterated RatingHold
i
1/21/2019BarclaysReiterated RatingEqual weight
i
1/15/2019BarclaysReiterated RatingEqual weight
i
1/7/2019Peel HuntReiterated RatingHold
i
1/2/2019JPMorgan Chase & Co.Lower Price TargetNeutralGBX 1,900 ➝ GBX 1,800
i
12/19/2018BarclaysReiterated RatingEqual weight
i
12/7/2018BarclaysReiterated RatingEqual weight
i
12/6/2018Peel HuntReiterated RatingHold
i
11/27/2018Jefferies Financial GroupUpgradeBuyGBX 1,643 ➝ GBX 2,000
i
11/20/2018JPMorgan Chase & Co.Boost Price TargetNeutralGBX 1,050 ➝ GBX 1,900
i
11/12/2018Peel HuntDowngradeHoldGBX 1,950 ➝ GBX 2,000
i
11/9/2018BarclaysReiterated RatingEqual WeightGBX 1,950
i
11/8/2018Peel HuntReiterated RatingAdd
i
11/6/2018BarclaysUpgradeEqual weightGBX 1,400 ➝ GBX 1,800
i
11/1/2018Peel HuntReiterated RatingAdd
i
10/30/2018CitigroupReiterated RatingBuyGBX 2,250
i
10/23/2018Peel HuntReiterated RatingAdd
i
10/15/2018BarclaysReiterated RatingUnderweight
i
10/9/2018BarclaysReiterated RatingUnderweight
i
10/3/2018Peel HuntReiterated RatingAdd
i
10/3/2018CitigroupBoost Price TargetBuyGBX 2,100 ➝ GBX 2,250
i
9/24/2018BarclaysReiterated RatingUnderweight
i
9/17/2018BarclaysReiterated RatingUnderweight
i
9/4/2018Peel HuntReiterated RatingAdd
i
8/24/2018BarclaysReiterated RatingUnderweightGBX 1,400
i
8/21/2018JPMorgan Chase & Co.Reiterated RatingNeutralGBX 1,050
i
8/20/2018CitigroupBoost Price TargetBuyGBX 1,675 ➝ GBX 2,100
i
8/16/2018BarclaysReiterated RatingUnderweight
i
8/16/2018Peel HuntUpgradeAddGBX 1,160 ➝ GBX 1,950
i
8/15/2018Numis SecuritiesReiterated RatingHold
i
8/15/2018Peel HuntReiterated RatingHoldGBX 1,160
i
8/10/2018BarclaysReiterated RatingUnderweight
i
8/9/2018Numis SecuritiesDowngradeHoldGBX 1,560
i
8/1/2018Peel HuntReiterated RatingHold
i
7/19/2018BarclaysReiterated RatingUnderweight
i
7/10/2018BarclaysReiterated RatingUnderweight
i
7/3/2018CitigroupReiterated RatingBuyGBX 1,675
i
7/3/2018Peel HuntReiterated RatingHold
i
5/31/2018Peel HuntReiterated RatingHold
i
5/21/2018BarclaysReiterated RatingUnderweight
i
5/18/2018Numis SecuritiesDowngradeAddGBX 1,300 ➝ GBX 1,560
i
5/18/2018Jefferies Financial GroupReiterated RatingHoldGBX 997
i
5/18/2018Peel HuntReiterated RatingHold
i
5/1/2018CitigroupBoost Price TargetBuyGBX 1,250 ➝ GBX 1,475
i
4/4/2018Peel HuntReiterated RatingHold
i
3/20/2018Peel HuntLower Price TargetHoldGBX 1,180 ➝ GBX 1,160
i
3/19/2018BarclaysReiterated RatingUnderweightGBX 800 ➝ GBX 850
i
3/15/2018Morgan StanleyBoost Price TargetEqual weightGBX 1,000 ➝ GBX 1,050
i
3/15/2018CitigroupUpgradeBuyGBX 1,250
i
3/15/2018JPMorgan Chase & Co.Boost Price TargetNeutralGBX 1,000 ➝ GBX 1,050
i
3/15/2018Jefferies Financial GroupUpgradeHoldGBX 895 ➝ GBX 997
i
3/14/2018Peel HuntReiterated RatingHoldGBX 1,180
i
3/14/2018Numis SecuritiesInitiated CoverageBuyGBX 1,300
i
3/1/2018BarclaysDowngradeUnderweightGBX 1,500 ➝ GBX 800
i
2/15/2018Peel HuntLower Price TargetHoldGBX 1,390 ➝ GBX 1,180
i
2/1/2018Peel HuntReiterated RatingHoldGBX 1,390
i
1/17/2018Jefferies Financial GroupReiterated RatingUnderperformGBX 895
i
1/15/2018JPMorgan Chase & Co.Reiterated RatingNeutral
i
1/10/2018Jefferies Financial GroupDowngradeUnderperformGBX 1,074 ➝ GBX 895
i
12/20/2017Numis SecuritiesReiterated RatingBuyGBX 1,300
i
12/4/2017Jefferies Financial GroupBoost Price TargetHoldGBX 1,045 ➝ GBX 1,074
i
12/1/2017Morgan StanleyReiterated RatingEqual weightGBX 1,100
i
11/15/2017Peel HuntReiterated RatingHoldGBX 1,390
i
11/10/2017JPMorgan Chase & Co.Lower Price TargetNeutralGBX 1,250 ➝ GBX 1,000
i
11/9/2017Peel HuntReiterated RatingHoldGBX 1,390
i
11/9/2017Stifel NicolausLower Price TargetHoldGBX 1,320 ➝ GBX 1,000
i
11/9/2017Numis SecuritiesUpgradeBuyGBX 1,300
i
11/9/2017Jefferies Financial GroupReiterated RatingHoldGBX 1,045
i
10/31/2017Peel HuntReiterated RatingHoldGBX 1,390
i
10/6/2017JPMorgan Chase & Co.Lower Price TargetNeutralGBX 1,500 ➝ GBX 1,250
i
9/29/2017JPMorgan Chase & Co.Reiterated RatingNeutral
i
8/29/2017Stifel NicolausDowngradeHoldGBX 2,300 ➝ GBX 1,320
i
8/25/2017BarclaysLower Price TargetOverweightGBX 2,200 ➝ GBX 1,500
i
8/24/2017CitigroupReiterated RatingNeutralGBX 1,350
i
8/22/2017The Goldman Sachs GroupDowngradeNeutralGBX 2,600 ➝ GBX 1,310
i
8/21/2017Morgan StanleyDowngradeEqual weightGBX 1,600 ➝ GBX 1,350
i
8/21/2017Jefferies Financial GroupLower Price TargetHoldGBX 1,390 ➝ GBX 1,045
i
8/17/2017Numis SecuritiesReiterated RatingAddGBX 1,560
i
8/17/2017Peel HuntReiterated RatingHoldGBX 2,150
i
8/11/2017Numis SecuritiesReiterated RatingAddGBX 1,560
i
8/2/2017Morgan StanleyDowngradeEqual WeightGBX 2,050 ➝ GBX 1,600
i
7/3/2017BarclaysReiterated RatingOverweightGBX 2,200
i
6/28/2017CitigroupReiterated RatingNeutralGBX 1,550
i
6/28/2017Jefferies Financial GroupLower Price TargetUnderweightGBX 1,450 ➝ GBX 1,390
i
6/27/2017JPMorgan Chase & Co.Reiterated RatingNeutralGBX 1,500
i
6/2/2017Jefferies Financial GroupReiterated RatingUnderperformGBX 1,450
i
5/22/2017JPMorgan Chase & Co.Reiterated RatingNeutralGBX 1,800 ➝ GBX 1,500
i
5/19/2017Numis SecuritiesReiterated RatingAddGBX 2,000
i
5/17/2017Jefferies Financial GroupDowngradeUnderperformGBX 2,162 ➝ GBX 1,450
i
5/12/2017JPMorgan Chase & Co.Lower Price TargetNeutralGBX 2,400 ➝ GBX 1,800
i
5/11/2017Numis SecuritiesReiterated RatingBuyGBX 2,350
i
4/10/2017Numis SecuritiesUpgradeBuyGBX 2,350
i
4/6/2017JPMorgan Chase & Co.Reiterated RatingNeutralGBX 2,400
i
4/4/2017Stifel NicolausReiterated RatingBuyGBX 2,550
i
3/30/2017Numis SecuritiesReiterated RatingAddGBX 2,350
i
3/30/2017Peel HuntReiterated RatingBuy
i
3/28/2017JPMorgan Chase & Co.Reiterated RatingNeutralGBX 2,400
i
3/22/2017JPMorgan Chase & Co.Reiterated RatingNeutralGBX 2,400
i
3/16/2017JPMorgan Chase & Co.DowngradeNeutralGBX 2,100 ➝ GBX 2,400
i
3/15/2017Peel HuntReiterated RatingBuyGBX 2,340
i
3/13/2017JPMorgan Chase & Co.Reiterated RatingOverweight
i
3/10/2017Numis SecuritiesDowngradeAddGBX 2,350
i
2/24/2017Peel HuntReiterated RatingBuyGBX 2,340
i
1/25/2017Peel HuntInitiated CoverageBuyGBX 2,340
i
1/17/2017Jefferies Financial GroupBoost Price TargetBuyGBX 2,065 ➝ GBX 2,162
i
1/17/2017JPMorgan Chase & Co.Reiterated RatingOverweightGBX 2,100
i
1/4/2017JPMorgan Chase & Co.Lower Price TargetOverweightGBX 2,450 ➝ GBX 2,100
i
12/15/2016Jefferies Financial GroupBoost Price TargetBuyGBX 2,000 ➝ GBX 2,065
i
12/6/2016JPMorgan Chase & Co.Reiterated RatingOverweightGBX 2,450
i
11/30/2016AlphaValueReiterated RatingBuyGBX 2,431
i
11/17/2016JPMorgan Chase & Co.Reiterated RatingOverweight
i
11/16/2016CitigroupReiterated RatingNeutral
i
11/15/2016Morgan StanleyUpgradeEqual Weight ➝ OverweightGBX 2,500 ➝ GBX 2,200
i
11/11/2016JPMorgan Chase & Co.Reiterated RatingOverweight
i
11/11/2016Jefferies Financial GroupLower Price TargetBuyGBX 2,500 ➝ GBX 2,000
i
11/10/2016Numis SecuritiesReiterated RatingBuyGBX 2,350
i
11/4/2016Numis SecuritiesUpgradeBuyGBX 2,350
i
9/23/2016JPMorgan Chase & Co.Reiterated RatingOverweight
i
9/14/2016JPMorgan Chase & Co.Lower Price TargetOverweightGBX 2,550 ➝ GBX 2,450
i
9/12/2016Jefferies Financial GroupLower Price TargetBuyGBX 2,990 ➝ GBX 2,500
i
9/9/2016BarclaysReiterated RatingOverweightGBX 2,900
i
8/24/2016Numis SecuritiesReiterated RatingHoldGBX 2,660
i
8/23/2016JPMorgan Chase & Co.Reiterated RatingOverweightGBX 2,550
i
8/16/2016JPMorgan Chase & Co.Reiterated RatingOverweightGBX 2,550
i
8/12/2016Morgan StanleyLower Price TargetEqual weightGBX 2,700 ➝ GBX 2,500
i
8/4/2016CitigroupDowngradeNeutralGBX 2,600
i
8/4/2016JPMorgan Chase & Co.Lower Price TargetOverweightGBX 2,800 ➝ GBX 2,550
i
8/4/2016Numis SecuritiesDowngradeHoldGBX 2,660
i
8/4/2016Jefferies Financial GroupReiterated RatingBuyGBX 2,990
i
8/4/2016BarclaysReiterated RatingOverweightGBX 2,800
i
7/26/2016Jefferies Financial GroupBoost Price TargetBuyGBX 2,800 ➝ GBX 2,990
i
7/22/2016Numis SecuritiesInitiated CoverageAddGBX 2,830
i
7/21/2016Morgan StanleyInitiated CoverageEqual weightGBX 2,700
i
7/5/2016Jefferies Financial GroupBoost Price TargetBuyGBX 2,380 ➝ GBX 2,800
i
6/24/2016Stifel NicolausReiterated RatingBuy
i
(Data available from 6/14/2016 forward)
Hikma Pharmaceuticals logo
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment develops, manufactures, and sells generic injectable products primarily for use in hospitals. The Generics segment develops, manufactures, and sells oral and other non-injectable generic products for the retail market. The Branded segment develops, manufactures, markets, and sells branded generics and in-licensed products to retail and hospital markets. The company offers its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, anesthetic, sedative, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.
Read More

Today's Range

Now: GBX 2,468
2,451
2,469

50 Day Range

MA: GBX 2,400.68
2,301
2,496

52 Week Range

Now: GBX 2,468
2,086.49
2,768

Volume

12,275 shs

Average Volume

393,379 shs

Market Capitalization

£5.71 billion

P/E Ratio

19.31

Dividend Yield

1.50%

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Hikma Pharmaceuticals?

The following sell-side analysts have issued stock ratings on Hikma Pharmaceuticals in the last twelve months: Barclays PLC, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Morgan Stanley, and Peel Hunt.
View the latest analyst ratings for HIK.

What is the current price target for Hikma Pharmaceuticals?

4 Wall Street analysts have set twelve-month price targets for Hikma Pharmaceuticals in the last year. Their average twelve-month price target is GBX 2,717.50, suggesting a possible upside of 10.1%. Peel Hunt has the highest price target set, predicting HIK will reach GBX 2,860 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of GBX 2,600 for Hikma Pharmaceuticals in the next year.
View the latest price targets for HIK.

What is the current consensus analyst rating for Hikma Pharmaceuticals?

Hikma Pharmaceuticals currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HIK will outperform the market and that investors should add to their positions of Hikma Pharmaceuticals.
View the latest ratings for HIK.

What other companies compete with Hikma Pharmaceuticals?

How do I contact Hikma Pharmaceuticals' investor relations team?

Hikma Pharmaceuticals' physical mailing address is 1 New Burlington Place, LONDON, W1S 2HR, United Kingdom. The company's listed phone number is +44-20-73992760. The official website for Hikma Pharmaceuticals is www.hikma.com.